Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized placebo-controlled dose-escalation study of AQX-1125 in healthy volunteers
NL-OMON34539Phase 1Active, not recruiting
- Sponsor
- Aquinox Pharmaceuticals
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in Inflammatory Disorders, asthma and arthritis comparing AQX-1125 with Placebo (2 arms). Primary endpoints: Safety and tolerability after single ascending doses, Safety and tolerability after multiple ascending doses and 2 more. Started Jan 2011; status: active, not recruiting.
02
Drugs
AQX-1125
03
Conditions
Inflammatory Disordersasthmaarthritis
Beyond the preview
Go deeper on NL-OMON34539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34539.